Why Biomarker-Driven Treatment Fails The Hidden Role of Histology Introduction Biomarker-driven treatment has fundamentally transformed oncology, ushering in an era of precision medicine in which therapeutic decisions are increasingly guided by the molecular characteristics of tumors rather than their anatomical origin alone. A
Oncology
Targeting the Bone Marrow Microenvironment in Myeloma and Acute Myeloid Leukemia: Novel Therapeutic Approaches and Clinical Implications
Targeting the Bone Marrow Microenvironment in Myeloma and Acute Myeloid Leukemia Novel Therapeutic Approaches and Clinical Implications Abstract The bone marrow microenvironment is increasingly recognized as a central determinant in the initiation, progression, and therapeutic resistance of hematologic malignancies, particularly multiple myeloma and acute myeloid leukemia
Bite Therapy: CAR-T vs T-Cell Engagers – Which Saves More B-ALL Patients?
Bite Therapy: CAR-T vs T-Cell Engagers – Which Saves More B-ALL Patients? Introduction Bite therapy and CAR-T cell treatments have revolutionized the management of B-cell acute lymphoblastic leukemia (B-ALL), achieving remarkable remission rates. Second-generation CD19-targeted chimeric antigen receptor T cells achieve dramatic remission
Skyrocketing Cancer Drug Prices: Can Oncologists Influence Policy?
Skyrocketing Cancer Drug Prices Can Oncologists Influence Policy Abstract The rapid escalation of cancer drug prices has emerged as a major challenge in contemporary oncology practice, with many newly approved therapies carrying annual costs that exceed one hundred thousand dollars per patient. This
Radioligand Therapy Results: New Evidence in Treating Neuroendocrine Tumors
Radioligand Therapy Results New Evidence in Treating Neuroendocrine Tumors Check out our extensive video library (see channel for our latest videos) Introduction Radioligand therapies have emerged as an important breakthrough in the management of neuroendocrine tumors, a group of heterogeneous neoplasms known
PARP Inhibitors in Pancreatic Cancer: Breaking Beyond BRCA Mutations
PARP Inhibitors in Pancreatic Cancer: Breaking Beyond BRCA Mutations Check out our extensive video library (see channel for our latest videos) Introduction PARP inhibitor therapy for pancreatic cancer represents one of the most significant breakthroughs in precision oncology. These targeted therapies have
KRAS G12C Inhibitors: Breaking the 40-Year Drug Development Barrier
FDA-Approved ADCs: Breaking New Ground in Breast, Lung, and Gastric Cancer Treatment
FDA-Approved ADCs: Breaking New Ground in Breast, Lung, and Gastric Cancer Treatment Check out our extensive video library (see channel for our latest videos) Introduction FDA-approved ADCs are revolutionizing cancer treatment landscapes, as the fifth most prevalent malignancy globally, gastric cancer ranks
Critical Updates in TP53 MDS Prognosis: 2025 Findings
Hemophilia Prophylaxis in the Era of Non-Factor Therapies
Hemophilia Prophylaxis in the Era of Non-Factor Therapies Check out our extensive video library (see channel for our latest videos) Abstract Hemophilia treatment has changed dramatically with the introduction of non-factor therapies. This paper examines how these new treatments affect prophylactic care for
